The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Open accessAbstract
1. Preamble 4361 2. Introduction 4363 3. Estimation of total cardiovascular risk and implications for dyslipidaemia management 4363 4. New low-density lipoprotein cholesterol-lowering therapies 4367 5. Combination of lipid-lowering therapies during index hospitalization for acute coronary syndromes 4369 6. Lipoprotein(a) 4370 7. Hypertriglyceridaemia 4371 8. Primary prevention in people with human immunodeficiency virus infection 4372 9. Patients with cancer at high or very high chemotherapy-related cardiovascular toxicity risk 4373 10. Dietary supplements 4373 11. Evidence tables 4374 12. Data availability statement 4374 13. Author information 4374 14. Appendix 4374 15. References 4375 Recommendation Table 1 — Recommendations for cardiovascular risk estimation in persons without known cardiovascular disease (see also Supplementary data online, Evidence Table 1) 4367 Recommendation Table 2 — Recommendations for pharmacological low-density lipoprotein cholesterol lowering (see also Supplementary data online, Evidence Table 2) 4369 Recommendation Table 3 — Recommendations for lipid-lowering therapy in patients with acute coronary syndromes (see also Supplementary data online, Evidence Table 3) 4370 Recommendation Table 4 — Recommendations for measurement of lipoprotein(a) (see also Supplementary data online, Evidence Table 4) 4370 Recommendation Table 5 — Recommendations for drug treatment of patients with hypertriglyceridaemia (see also Supplementary data online, Evidence Table 5) 4372 Recommendation Table 6 — Recommendations for statin therapy in primary prevention for people with human immunodeficiency virus infection (see also Supplementary data online, Evidence Table 6) 4373 Recommendation Table 7 — Recommendations for statin therapy in patients receiving cancer therapy (see also Supplementary data online, Evidence Table 7) 4373 Recommendation Table 8 — Recommendations for dietary supplements (see also Supplementary data online, Evidence Table 8) 4374 Table 1 Classes of recommendations 4362 Table 2 Levels of evidence 4362 Table 3 Cardiovascular risk categories 4364 Table 4 Intervention strategies as a function of total cardiovascular risk and untreated low-density lipoprotein cholesterol levels 4365 Figure 1 Treatment goals for low-density lipoprotein cholesterol across categories of total cardiovascular risk 4366 Figure 2 Average reduction in low-density lipoprotein cholesterol levels with different pharmacological therapies with proven cardiovascular benefits 4368 Figure 3 Association between Lp(a) levels and lifetime risk of major cardiovascular events 4371 Acute coronary syndromes Alanine aminotransferase Apolipoprotein B Apolipoprotein C-III Antiretroviral therapy Atherosclerotic cardiovascular disease Aspartate aminotransferase Aortic valve stenosis Coronary artery calcium Confidence interval Computed tomography Cardiovascular Cardiovascular disease Docosahexaenoic acid European Atherosclerosis Society European Medicines Agency Eicosapentaenoic acid European Society of Cardiology Familial chylomicronaemia syndrome US Food and Drug Administration Familial hypercholesterolaemia High-density lipoprotein cholesterol Human immunodeficiency virus Hazard ratio Low-density lipoprotein cholesterol Lipoprotein(a) Left ventricular ejection fraction Monoclonal antibody Major adverse cardiovascular event(s) Myocardial infarction Percutaneous coronary intervention Proprotein convertase subtilisin/kexin type 9 Peroxisome proliferator-activated receptor n-3 polyunsaturated fatty acid People with HIV Systematic Coronary Risk Evaluation 2 Systematic Coronary Risk Evaluation 2-Older Persons Total cholesterol Type 1 diabetes mellitus Type 2 diabetes mellitus Upper limit of normal Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approach for an individual patient with a given condition. The European Society of Cardiology (ESC) Guidelines are intended for use by health professionals but do not override their individual responsibility to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with the patient or the patient's caregiver where appropriate and/or necessary aiming at shared care decisions. It is also the health professional's responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription and to respect the ethical rules of their profession. The ESC Guidelines represent the official position of the ESC on a given topic. Guideline topics are selected for updating after annual expert review of new evidence conducted by the ESC Clinical Practice Guidelines (CPG) Committee. ESC Policies and Procedures for formulating and issuing the ESC Guidelines can be found on the ESC website (https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines). Interim
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, the guidelines highlight that variability in LDL-C lowering is observed across all treatment options, likely reflecting differences in background LLT regimens [45].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with this, they emphasize the importance of monitoring LDL-C response 4 to 6 weeks after initiation or intensification and making timely treatment adjustments to achieve recommended targets [45].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recent ESC/EAS 2025 Focused Update Guideline [9] emphasizes that elevated TG and TRLs contribute independently to cardiovascular risk, even in patients achieving LDL-C targets.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recent 2025 ESC/EAS Focused Update confirms this guidance, emphasizing the persistent role of statins as the cornerstone therapy for cardiovascular risk reduction in the presence of elevated TG, not only by targeting LDL-C but also by modulating TRLs and reducing the atherogenic potential of the lipid profile [9].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The recommendations position bempedoic acid alongside other established LLTs with demonstrated cardiovascular-risk reduction such as statins, ezetimibe, and PCSK9i.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“Guidelines also recommend that the choice of treatment should not only be made based on the magnitude of additional LDL-C lowering needed, but also patient preference, treatment availability, and cost [45].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“The 2025 ESC/EAS guidelines for the management of dyslipidemia provide new recommendations for bempedoic acid in both patients unable to take statins and as an adjunct to maximally tolerated statin therapy, with or without ezetimibe, including use in high- and very high-risk patients [45].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“the 2025 ESC/EAS Focused Update [9] emphasizes that consistent cardiovascular benefit has not been demonstrated in the overall population, and fibrate therapy should therefore be reserved for carefully selected patients with persistent hypertriglyceridaemia or features of atherogenic dyslipidemia despite optimal LDL-C lowering”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Overall, the joint guideline recognizes TG/TRL-mediated risk as a modifiable component of residual cardiovascular risk, addressed pragmatically through non–HDL-C/apoB targets and selective TG-lowering therapies integrated with intensive LDL-C reduction, with non-fasting testing as the default approach.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Self-citation2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Self-citationEzetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citation2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C. J., Andreotti, F., Koskinas, K. C., Rosselló, X., Adamo, M., Ainslie, J., BANNING, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 3,521
Self-citationLyon, A. R., López‐Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J. K., Boriani, G., Cardinale, D. M., Córdoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,457
Self-citationCardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Cited by
Sorted by citations
Items 201–300 of 817
Yılmaz, O., Seçkin, Ö., & Ünlü, S. (2026) · Angiology · doi:10.1177/00033197261427073 · Cited by 1
Luca, S. A., Bungau, R. M., Herascu, A., Albai, A., Lazăr, S., & Timar, B. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041674 · Cited by 1
Ezetimibe alone for over 75 years old as a primary prevention to decrease cardiovascular events
Vuorio, A. F., Kovanen, P. T., & Strandberg, T. E. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2634484 · Cited by 1
Turgul, C., & Keleşoğlu, Ş. (2026) · Diagnostics · doi:10.3390/diagnostics16050647 · Cited by 1
Gołdyn, M. J., Lichoń, J. M., Kras, M., Karasiewicz, A., Kuklo, M., Łepecki, D., Karolak, A., & Jakubowska, E. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.5040 · Cited by 1
Popiołek-Kalisz, J., & Sabouret, P. F. (2026) · Advances in Medical Sciences · doi:10.1016/j.advms.2026.02.006 · Cited by 1
Upfront Combination or Stepwise Escalation: Personalising LDL-C Reduction in Clinical Practice
Pirillo, A., & Catapano, A. L. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01400-8 · Cited by 1
Self-citationLu, X., Yuan, Z., Lin, X., Huang, Z., Zhou, Z., Huang, H., Li, Y., Zhang, S., Hui, Z., Ling, Y., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70603 · Cited by 1
Asano, T., Sawano, M., Kohsaka, S., Ishii, H., Matoba, T., Aoki, J., Amano, T., & Kozuma, K. (2026) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-026-01247-5 · Cited by 1
Mohamed, D. A., Elbakry, H. F. H., Gamil, I., Abdelgayed, S. S., & Mabrok, H. B. (2026) · Applied Biosciences · doi:10.3390/applbiosci5010017 · Cited by 1
Präventionsfelder der Endokrinologie/Diabetologie – „The Big Five“
Pfohl, M., Reincke, M., Seufert, J., Feldkamp, J., Faßnacht, M., Merkel, M., & Tuckermann, J. (2026) · Die Innere Medizin · doi:10.1007/s00108-026-02094-5 · Cited by 1
Early atheroma prevention: a cost-effective approach to healthy cardiovascular ageing
Steinhauer, R., Xu, J. Y. H., Blumenthal, R. S., & Troy, A. L. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00419-8 · Cited by 1
Uslu, S., & Öztekin, G. M. Y. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062312 · Cited by 1
The ABCs of cardiovascular disease prevention: communicating what we know in 2026
Goren, L. R., Peng, A. W., Razavi, A. C., Blaha, M. J., Blumenthal, R. S., & Troy, A. L. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101570 · Cited by 1
Ray, K. K., Aguiar, C., Arca, M., Connolly, D. L., Eriksson, M., Ferrières, J., Laufs, U., Mostaza, J., Nanchen, D., Boachie, C., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101577 · Cited by 1
Self-citationMuszyński, P., Kazberuk, M., Kruszyńska, J., Wilk‐Śledziewska, K., Kazberuk, P., Musiałowska, D., Groth, M., & Dudzińska, K. (2026) · Diseases · doi:10.3390/diseases14040125 · Cited by 1
The Past, Present, and Future of Dyslipidemia: A Narrative Review
Manoria, P. C. (2026) · Cureus · doi:10.7759/cureus.106258 · Cited by 1
Genetic Association Study of IL23R and IL12B Polymorphisms with Psoriasis in a Romanian Population
Matei-Man, A.-M., Gaal, O. I., Catana, A., Vesa, Ș. C., Șenilă, S. C., Candrea, E., Orăsan, M. S., Pușcaș, A. D., Man, A. C., & Mocan, T. (2026) · Life · doi:10.3390/life16040574 · Cited by 1
Lipoprotein(a) in Cardiovascular Disease: What Clinicians Need to Know: A Narrative Review
Ricottini, E., Ciavaroli, N. G., Cristo, A. D., Lentini, A. E., Trunfio, T. A., D’Antonio, L., Mangiacapra, F., Nusca, A., Cammalleri, V., Melfi, R., et al. (2026) · Therapeutics · doi:10.3390/therapeutics3020011 · Cited by 1
Zingano, C. P., Brennan, D. M., Bloedon, L. T., Li, N., Herout, P. M., Powell, H. A., Spiazzi, B. F., Ray, K. K., Nicholls, S. J., Nissen, S. E., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag195 · Cited by 1
Self-citationConsolim‐Colombo, F. M., Précoma, D. B., Camazzola, F. E., ABIB, E., Franco, D. R., Magalhães, L. B. N. C., Spinelli, A. C. D. S., Gemelli, J. R., Borges, J. L. C., Montenegro, R. M., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15083022 · Cited by 1
Bariatric surgery attenuates the age-related increase in cardiovascular risk over 10 years
Benaiges, D., Olano, M., Masip, N., Ballesta, S., Casajoana, A., Pérez, K. A., Roux, J. A. F., Climent, E., Subirana, I., Castañer, O., et al. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104750 · Cited by 1
Caldeira, D., alves, M. D. G., Avó-Baião, R., Lopes, A. R., Prada, L., & Pinto, F. J. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-026-00795-8 · Cited by 1
Schrenk, M., Haenelt, M., Oettle, M., Kroiss, M., Zopp, S., Braun, L., Rubinstein, G., Ritzel, K., Stüfchen, I., Stifel, U., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag178 · Cited by 1
Paquette, M., Thanassoulis, G., Sherman, M. H., Blank, D. W., & Baass, A. W. (2026) · Clinical Chemistry · doi:10.1093/clinchem/hvag038 · Cited by 1
Naiini, M. R., Jafari, A., & Shahouzehi, B. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02235-9 · Cited by 1
Gouda, P., Secemsky, E. A., Hess, C. N., Arya, S., Fokorede, F., Mehran, R., Bonaca, M. P., Patel, M. R., & Jones, W. S. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107446 · Cited by 1
Federici, M., Buzzetti, R., Candido, R., Cosmo, S. D., Pirillo, A., Russo, G., Sesti, G., & Avogaro, A. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03185-1 · Cited by 1
Jamakovic, M., Šljivo, A., Durak-Nalbantić, A., Ljuca, F., Bajrić, M., & Hukeljić-Berberović, B. (2026) · Medical Sciences · doi:10.3390/medsci14020227 · Cited by 1
Management of dyslipidaemia in patients with comorbidities—facing the challenge: heart failure
Drexel, H., Frick, M., Zirlik, A., Niessner, A., Huber, K., Tamargo, J., Dobrev, D., MADER, A., & Agewall, S. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag033 · Cited by 1
Self-citationWhat’s new in the AHA/ACC 2026 guidelines for the management of dyslipidemia?
Chełstowska, B., Kobayashi, A., Kopiec-Ostrowska, M. A., & Szymański, F. M. (2026) · Acta Angiologica · doi:10.5603/aa.111819 · Cited by 1
Impact of lipoprotein(a) on the durability of aortic bioprosthetic valves
Syryca, F., Krefting, J., Oertel, E., Wirth, F., Pellegrini, C., Rheude, T. A., Mayr, N. P., Holdenrieder, S., Alvarez‐Covarrubias, H. A., von Scheidt, M., et al. (2026) · Clinical Research in Cardiology · doi:10.1007/s00392-026-02933-3 · Cited by 1
Mental Disorders as Risk Factors for New Onset Cardiovascular Diseases
Sakowicz-Hriscu, A. A., Grunwald, O., Muszyński, P., Kożuch, M., & Dobrzycki, S. (2026) · Biomedicines · doi:10.3390/biomedicines14051138 · Cited by 1
Triglycerides and Residual Risk, Where Do They Fit Now?
Nordestgaard, B. G. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5133 · Cited by 1
Self-citationLipid-Lowering Therapy in the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia
Li, J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.03.069 · Cited by 1
Dyslipidemia Guideline Development
Blumenthal, R. S., & Morris, P. B. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.03.059 · Cited by 1
Fish oil supplements in patients with chronic kidney disease
Ferro, C. J., Thomas, M. R., Khattak, S., Chanouzas, D., & Townend, J. (2026) · Clinical Kidney Journal · doi:10.1093/ckj/sfag168 · Cited by 1
Update on Investigation and Management of Dyslipidaemias and Cardiovascular Disease Risk
Antwi, K., Luvai, A., Downie, P., Ghani, A., Maple, M., & Mbagaya, W. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm54141 · Cited by 1
Marzano, F., Nardi, E., Cotticelli, C., Santo, M. D., Agizza, S., Abbellito, G. M., Filardi, F. P., Liccardi, L., Sarno, S. D., Martone, I., et al. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13060234 · Cited by 1
Wang, Y. H., Liu, J. Y., Li, X., Ruzemaimaiti, S., Li, C. H. P., Liu, Y., & Gao, J. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1829711 · Cited by 1
Κόλλιας, Α., Kyriakoulis, K. G., Komnianou, A., Τσαγανός, Θ., Krystallaki, D., Menti, A., Antonogiannaki, E.-C., & Stergiou, G. S. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104823 · Cited by 1
Mwipatayi, B. P., Dodd, J., Carnagarin, R., Mori, T. A., Golledge, J., Burrows, S., Watts, G. F., Iida, O., & Schlaich, M. P. (2026) · Journal of Clinical Hypertension · doi:10.1111/jch.70309 · Cited by 1
Molinari, C., Galotta, A., Mushtaq, S., Frigerio, B., Vavassori, C., Rondinelli, M., Cosentino, N., Romandini, A., Chiesa, M., Vinci, M. C., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03245-6 · Cited by 1
Černiauskas, L., Palšytė, V., Aleknavičiūtė-Valienė, G., Mazgelytė, E., Bikulčienė, I., Badarienė, J., Rinkūnienė, E., Arbaciauskaite, S., Allelein, S., & Karčiauskaitė, D. (2026) · Antioxidants · doi:10.3390/antiox15060731 · Cited by 1
Cesaro, A., Jamialahmadi, O., Pugliese, N., Flagiello, V., Barreby, E., Mancina, R. M., Calabrò, P., & Romeo, S. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101706 · Cited by 1
Návar, A. M., Bai, L., Højen, J. F., Ivanes, F., Kristensen, S. L., Lam, C. S. P., Landmesser, U., Lee, K., Liuzzo, G., Maia, L. N., et al. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120816 · Cited by 1
Self-citationOptimizing lipoprotein(a) testing for immediate clinical impact in primary prevention
Björnson, E., Hagström, E., Littmann, K., Östgren, C. J., Söderberg, S., Engström, G., Hogling, D. E., Bergström, G. M. L., & Brinck, J. W. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120826 · Cited by 1
Sinning, D., & Landmesser, U. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag456 · Cited by 1
Self-citationSandslatt, J., Boström, K. B., Åberg, M., Bager, J., Simons, K. S., Mourtzinis, G., Hjerpe, P., & Andersson, T. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag048 · Cited by 1
First count the particles: ApoB, the LDL-C/TC ratio, and the hierarchy of lipid risk assessment
Arnold, N., & Köenig, W. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag339 · Cited by 1
Minutolo, R., Nicola, L. D., Cesaro, A., Cozzolino, M. G., Lullo, L. D., Iacoviello, M., Paoletti, E., Ravera, M., & Russo, V. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01434-y · Cited by 1
Wang, J., Wan, Q., Huang, Z., Huang, Y. Q., Zhang, B., & Wen, S. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13070320 · Cited by 1
Cardiovascular risk in inflamed Danish women and men without standard modifiable risk factors
Nordestgaard, A. T., Ridker, P. M., & Nordestgaard, B. G. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag349 · Cited by 1
Self-citationLago‐Rodríguez, M., Sánchez, M. S., Torres, A., Díez, C., Fanciulli, C., Pérez, L., Tejerina, F., Bello-Martínez, E., Bellón, J. M., Muñóz, P., et al. (2026) · Clinical Medicine · doi:10.1016/j.clinme.2026.100625 · Cited by 1
Wang, H., & Ge, S. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107061 · Cited by 1
EndoBridge 2025: pearls and highlights
Yıldız, B. O., Armenti, M., Brandi, M. L., Carey, J., Carling, T., Ciudin, A., Dhatariya, K., Fountas, A., Frühbeck, G., Goulis, D., et al. (2026) · HORMONES · doi:10.1007/s42000-026-00804-0 · Cited by 1
Targeting Interleukin-6 for Treatment of CKD and Cardiovascular Disease
Tuttle, K. R., Cherney, D. Z. I., Pecoits-Filho, R., Pirro, M., Yau, K., & Sahay, M. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106712 · Cited by 1
Avidan, Y., Kobo, O. M., Weizman, B., Jonas, M., Hadar, D., Zafrir, B., & Kassem, S. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07918-y · Cited by 1
Longer-term efficacy and safety of zodasiran in patients with mixed hyperlipidaemia
Rosenson, R. S., Gaudet, D., Ballantyne, C. M., Nicholls, S. J., Lucas, K. J., Leeper, N. J., Zhou, R., Aiyer, L., Hellawell, J. L., & Watts, G. F. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag376 · Cited by 1
Sniderman, A. D., Pencina, K. M., Thanassoulis, G., Dufresne, L., & Pencina, M. J. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag400 · Cited by 1
Tatuene, J. K., Farrell, J., Nolan, J., Lessels, S., Whiteley, W. N., & Li, L. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1004999 · Cited by 1
Lipoprotein(a): from the complex metabolism to the optimal lowering drug
Barbagallo, F. D. G., Berteotti, M., Bosco, G., Cosco, L., Pino, A. D., Alfano, F., Piro, S., Scicali, R., Masana, L., & Marcucci, R. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04492-x · Cited by 1
Lipoprotein(a) in Japan: when ‘moderately elevated’ might already mean high risk
Kronenberg, F. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag607 · Cited by 1
Comparison of the 2025 ESC/EAS and 2026 ACC/AHA guidelines for dyslipidaemia management
Finocchiaro, S., Mauro, M. S., Bordonaro, C., Bujak, K., Cosentino, C., Cutore, L., Leo, G. D., Nasisi, F., Redigolo, P., & Capodanno, D. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag413 · Cited by 1
Efficacy and safety of olezarsen in patients with vs without baseline fibrate use
Wang, A. Z., Alexander, V. J., Prohaska, T. A., Ran, X., Goodrich, E. L., Murphy, S. A., Zimerman, A., Moura, F. A., Kang, Y. M., Nordestgaard, B. G., et al. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.08.001 · Cited by 1
Self-citationChen, G., Lan, Y., Wu, D., Liu, P., Zheng, H., Wang, Y., Chen, Y., & Chen, Z. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1901020 · Cited by 1
Benedetto, C., Khadilkar, S. S., Nappi, R. E., Genazzani, A. R., Frezet, F., Cucinella, L., Divakar, H., Anagnostis, P. G., & Panay, N. (2026) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.71217 · Cited by 1
Lowering cumulative LDL-C exposure: the case for early treatment
Bajaj, A., & Cuchel, M. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag551 · Cited by 1
Banach, M., Ceasovschih, A., Surma, S., Alnouri, F., Mancini, G. J., Vinereanu, D., Yeh, H., Reiner, Z., Sabouret, P. F., Al-Khnifsawi, M., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101808 · Cited by 1
Self-citationWood, D. R., Jennings, C. S., Kotseva, K., Adamska, A., Erlund, I., Ganly, S., Groop, P., Hennessy, S., Leening, M. J. G., Mellbin, L., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag741 · Cited by 1
Self-citationLipoprotein(a) and Atherosclerotic Cardiovascular Disease Among Adults Aged 20 to 100 Years
Jeevanathan, J., Thomas, P. E., Kamstrup, P. R., & Nordestgaard, B. G. (2026) · Circulation · doi:10.1161/circulationaha.126.079412 · Cited by 1
Self-citationProtocol-Based Implementation of Early Intensive Lipid Management After Acute Coronary Syndrome
Oyama, K., Takahashi, J. T., Funaki, T., Oyamada, S., Horiguchi, S., Nakamura, A., Yagi, T., Ogata, K., Yahagi, H., Iwabuchi, K., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.08.026 · Cited by 1
Patoulias, D., Karagiannidis, E., Maragkoudakis, S., Alexanian, I. P., Papadopoulos, C., & Fragakis, N. (2026) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2026.08.007 · Cited by 1
Wang, H., Ma, Z., Gong, H., Zou, Y., Zhang, H., Chen, X., & Mao, X. (2026) · Nutrients · doi:10.3390/nu18172934 · Cited by 1
Shen, J., Wu, Y., & Wang, B. (2026) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.70877 · Cited by 1
Pan, Y.-T., Tsai, Y., Weng, H., Lee, J., Yang, J., Lin, L.-C., & Huang, Y.-C. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.048729 · Cited by 1
Cole, J., Dufresne, L., Toth, P. P., Langlois, M., Thanassoulis, G., & Sniderman, A. D. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.009 · Cited by 1
Patti, G., & Grisafi, L. (2026) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001932 · Cited by 1
Davies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Dragomir, T. L., Branea, H. S., Andor, M., Citu, I. M., Căruntu, F. R., Șușan, M. M., Oprean, C. M., Dragomir, R.-T., Șușan, R. M., Huțanu, D., et al. (2026) · Diagnostics · doi:10.3390/diagnostics16193245 · Cited by 1
Lipidtherapie bei Patienten mit Diabetes mellitus – Praxisempfehlung der DDG, DGE und DGK
Parhofer, K. G., Birkenfeld, A. L., Krone, W., Lehrke, M., Marx, N., Merkel, M., Marx-Schütt, K., Zirlik, A., & Müller‐Wieland, D. (2026) · Diabetologie und Stoffwechsel · doi:10.1055/a-2891-4582 · Cited by 1
Self-citationHayakawa, H., Tanaka, A., & Morikawa, S. (2026) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001945 · Cited by 1
Gender-Specific Perspectives on National and Global Dyslipidemia Guidelines
Takahashi, S., Matsukage, T., Koh, A. S.-M., Krishna, S., & Parvathaneni, N. S. H. (2025) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_63_2025 · Cited by 1
Reply letter to “Statin-associated myopathy risk in people with HIV-1 infection”
Gazzaniga, G., Pastori, D., & Mezzaroma, I. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104461 · Cited by 1
OSA, CPAP, and the impact on cardiometabolic parameters: what is next?
Drager, L. F. (2025) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2025.102213 · Cited by 1
ESC/EAS 2025 dyslipidaemia guidelines update: Don’t get left behind!
Bergerot, C., Groisne, L., Emmerich, J., Diévart, F., & Boccara, F. (2025) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2025.11.006 · Cited by 1
Self-citationTudoran, C., & Cozma, D. C. (2026) · Biomedicines · doi:10.3390/biomedicines14010250 · Cited by 1
Imaging-guided dyslipidemia management: Bridging evidence and implementation
Κόλλιας, Α., Krystallaki, D., & Τσαγανός, Θ. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106937 · Cited by 1
Effective Lowering of Lipoprotein (a) - A New Frontier in Cardiovascular Risk Reduction
Mukherjee, D., & Lange, R. A. (2026) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x520042260627210331 · Cited by 1
Lipoprotein(a) After HORIZON: Causal Culprit, Risk Marker, or Unfulfilled Therapeutic Promise?
Borovac, J. A., & Belančić, A. (2026) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484261492865 · Cited by 1
Targeting triglycerides for cardiovascular risk reduction
Maiorca, C., Tramontano, D., Di Costanzo, A., & D’Erasmo, L. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04383-1
Dziewierz, A., Bobrowska, B., Streb, W., Pelliccia, F., Bartuś, S., & Rajtar-Salwa, R. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2570839
Dziewierz, A., Maruszak, N., & Rakowski, T. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104376
Congress Feature: New ESC Guidelines: Redefining Holistic Care in Cardiology
Enesco, A. (2025) · EMJ Cardiology · doi:10.33590/emjcardiol/vbzd6589
Fériz, K., Corral, P., Iriarte-Durán, M. B., Giraldo, C. M. G., Nardelli, N., Arias‐Valderrama, O., & Gómez-Ayala, M. C. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01613-2
Tackling lipoprotein (a) from heart to toes
Kalaja, I., & Espinola–Klein, C. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf670
Opportunistic Screening for Subclinical CAD in Immune-Inflammatory Diseases
Slipczuk, L. N., & Bhatt, D. L. (2025) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2025.10.007
Increasing use of non-statin and combination lipid-lowering therapies 2012–2025: a nationwide study
Katzmann, J. L., Kieble, M., Laufs, U., & Schulz, M. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf720
Self-citationLp(a) in Argentina: Regional data reinforce a global risk factor
Harb, T., Gerstenblith, G., & Leucker, T. M. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120572
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.102471
Self-citation
Metadata
- Authors
- Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., Delgado, V., Fabin, N., Ference, B. A., Graham, I. M., Landmesser, U., Laufs, U., Mihaylova, B., Nordestgaard, B. G., Richter, D. J., Sabatine, M. S., ESC/EAS Scientific Document Group, Mueller, C. E., Drexel, H., Abreu, A., Adamo, M., Aktaa, S., Asselbergs, F. W., Baldini, A., Boriani, G., Brida, M., Brodmann, M., Cenko, E., Dagres, N., Dopheide, J., Ebenbichler, C., Gandjbakhch, E., Gorog, D. A., Gouni-Berthold, I., Guasti, L., Heidecker, B., Ibanez, B., James, S., Juni, P., Kałużna-Oleksy, M., Krychtiuk, K. A., Lip, G. Y. H., Lorusso, R., Mahfoud, F., Metra, M., Moelgaard, I., Morais, J., Neubeck, L., Nissen, S. E., Osto, E., Parhofer, K. G., De Isla, L. P., Pesce, M., Petrulioniene, Z., Prescott, E., Rietzschel, E., Rocca, B., Rodriguez Palomares, J. F., Rossello, X., Sannino, A., Semb, A. G., Siller-Matula, J. M., Socrates, T., Tanner, F. C., Wojta, J., Zambon, A., Zeppenfeld, K., Laredj, N., Hayrapetyan, H., Speidl, W. S., Samadov, F., van de Borne, P., Kusljugic, Z., Postadzhiyan, A., Heracleous, H., Ostadal, P., Henriksen, F. L., Mohamed, M. S., Viigimaa, M., Juonala, M., Boccara, F., Chukhrukidze, A., Weingärtner, O., Marketou, M., Kiss, R. G., Sigurdsson, A. F., Maher, V., Henkin, Y., Nodari, S., Bekbossynova, M., Ibrahimi, P., Mirrakhimov, E., Jegere, S., Arnaout, S., Bheleel, O., Plisiene, J., Visser, L., Abela, M., Ivanov, V., Boskovic, A., Mbarek, N., Leening, M. J. G., Bosevski, M., Vesterbekkmo, E. K., Kubica, J., Ferreira, J., Pop, D., Stefanelli, U. M., Giga, V., Pella, D., Fras, Z., Fernandez-Olmo, R., Nilsson, L., Sudano, I., Marjeh, M. Y. B., Triki, F., Degertekin, M. M., Mitchenko, O., Banerjee, A., & Shek, A.
- Affiliations
- (Switzerland)
- (Netherlands)
- (Türkiye)
- (Spain)
- (United Kingdom)
- (Denmark)
- (Austria)
- (Italy)
- (Belgium)
- (Ireland)
- (Germany)
- (Greece)
- (United States of America)
- (Portugal)
- (Croatia)
- (France)
- (Sweden)
- (Poland)
- (Austria/Switzerland)
- (Italy/Saudi Arabia)
- (Lithuania)
- (Norway)
- Corresponding author
- Mach, François
- Koskinas, Konstantinos C
- ORCID
- Mach, François
- Koskinas, Konstantinos C
- Roeters van Lennep, Jeanine E
- Tokgözoğlu, Lale
- Badimon, Lina
- Baigent, Colin
- Benn, Marianne
- Binder, Christoph J
- Catapano, Alberico L
- De Backer, Guy G
- Delgado, Victoria
- Fabin, Natalia
- Graham, Ian M
- Landmesser, Ulf
- Laufs, Ulrich
- Mihaylova, Borislava
- Nordestgaard, Børge Grønne
- Richter, Dimitrios J
- Sabatine, Marc S
- Mueller, Christian Eugen
- Drexel, Heinz
- Abreu, Ana
- Adamo, Marianna
- Aktaa, Suleman
- Asselbergs, Folkert W
- Boriani, Giuseppe
- Brida, Margarita
- Brodmann, Marianne
- Cenko, Edina
- Dagres, Nikolaos
- Dopheide, Jörn
- Ebenbichler, Christoph
- Gandjbakhch, Estelle
- Gorog, Diana A
- Guasti, Luigina
- Heidecker, Bettina
- James, Stefan
- Krychtiuk, Konstantin A
- Lip, Gregory Y H
- Lorusso, Roberto
- Mahfoud, Felix
- Metra, Marco
- Neubeck, Lis
- Nissen, Steven E
- Osto, Elena
- Parhofer, Klaus G
- Pesce, Maurizio
- Prescott, Eva
- Rietzschel, Ernst
- Rocca, Bianca
- Sannino, Anna
- Semb, Anne Grete
- Siller-Matula, Jolanta M
- Socrates, Thenral
- Tanner, Felix C
- Wojta, Johann
- Zambon, Alberto
- Zeppenfeld, Katja
- Hayrapetyan, Hamlet
- Speidl, Walter Stefan
- Samadov, Fuad
- van de Borne, Philippe
- Postadzhiyan, Arman
- Henriksen, Finn Lund
- Juonala, Markus
- Boccara, Franck
- Chukhrukidze, Archil
- Weingärtner, Oliver
- Marketou, Maria
- Nodari, Savina
- Bekbossynova, Makhabbat
- Mirrakhimov, Erkin
- Bheleel, Osama
- Abela, Mark
- Ivanov, Victoria
- Leening, Maarten J G
- Bosevski, Marijan
- Vesterbekkmo, Elisabeth K
- Kubica, Jacek
- Ferreira, Jorge
- Pop, Dana
- Giga, Vojislav
- Pella, Daniel
- Sudano, Isabella
- Triki, Faten
- Mitchenko, Olena
- Banerjee, Amitava
- Shek, Aleksandr
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2025-08-29
- Volume
- 46
- Issue
- 42
- Pages
- 4359-4378
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W4413804012
- Cited by
- 688
- References
- 136
- Citations by year
- 2026: 601 · 2025: 87
- FWCI
- 649.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- dyslipidemia, dyslipidemia management, cardiovascular risk prediction, LDL-C lowering therapy, acute coronary syndrome, lipoprotein(a), hypertriglyceridemia, HIV infection, cancer patients, statins, dietary supplements, treatment goals, cardiovascular risk reduction, cardiovascular mortality, cardiovascular hospitalization, cardiovascular disease prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
